Johnson & Johnson closed the deal to buy Abiomed for $16.6 billion, or $380 per share. Abiomed shareholders may also receive another $35.00 per share, subject to certain commercial and clinical milestones.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept